Gunderson Capital Management LLC Makes New Investment in Novo Nordisk A/S $NVO

Gunderson Capital Management LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 69,211 shares of the company’s stock, valued at approximately $2,544,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quotient Wealth Partners LLC increased its stake in Novo Nordisk A/S by 2.0% in the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after buying an additional 177 shares in the last quarter. Certuity LLC lifted its position in shares of Novo Nordisk A/S by 3.6% in the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after acquiring an additional 177 shares in the last quarter. Oakworth Capital Inc. lifted its position in shares of Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after acquiring an additional 182 shares in the last quarter. True North Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after acquiring an additional 199 shares during the period. Finally, Asio Capital LLC boosted its stake in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock worth $274,000 after acquiring an additional 200 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 0.8%

Shares of NVO stock opened at $48.01 on Friday. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $71.79. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock’s 50-day moving average price is $43.79 and its 200-day moving average price is $45.83. The stock has a market capitalization of $214.36 billion, a price-to-earnings ratio of 11.27, a price-to-earnings-growth ratio of 4.30 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts predict that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wolfe Research assumed coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Finally, TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective on the stock. in a research report on Tuesday, March 10th. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.